← All Adc Therapeutics SA filings

Adc Therapeutics SA 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
ADCT
Adc Therapeutics SA
10-K: ADC Therapeutics Reports Promising Pipeline Progress in 2024, Eyes Strategic Partnerships
ADC Therapeutics' 2024 10-K filing highlights the company's focus on expanding ZYNLONTA's market and advancing its solid tumor pipeline through strategic collaborations.
NYSE
ADCT
Adc Therapeutics SA
10-K: ADC Therapeutics SA Details Share Capital, Articles of Association in SEC Filing
ADC Therapeutics SA, a Swiss stock corporation, outlines its share capital structure, registration rights agreements, and articles of association in its latest 10-K filing.